The Hub Commentary_
As I began reading this article I thought there is a CIO in tune with her business. R&D is the heart and soul of pharmaceutical companies and IT needs to work to drive business growth and cost saving in these days of transformation. AstraZeneca is on the outside of the recent Fortune 500 list, but if innovation continues with this strategy in mind, I would expect to see growth out of them in the coming years.
I found the commentary interesting that follows the article. Sales organizations have one and only one metric, are they selling and did they hit the number. Sales professionals know this and while AZ may have lost members of the sales organization for a variety of reasons, I suspect, I applaude the Angela’s strategic thinking and confidence not to take a back seat in driving innovation into the organization with technology.
I ask, how are you driving innovation into your organization with technology?
The strategic review undertaken each summer by pharmaceutical giant AstraZeneca acquired additional significance this year in the wake of a first quarter in which sales fell by 11%, to $7.3 billion, and earnings plummeted by 44%. Resultant investor criticism cost chief executive David Brennan and chairman Louis Schweitzer their jobs in recent weeks. (Read Full Article…)